Trials / Recruiting
RecruitingNCT07071714
A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer
An Open, Multicenter Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-8068 injection in combination with anti-tumor therapies in subjects with colorectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-8068 Injection | SHR-8068 injection. |
| DRUG | Adebrelimab Injection | Adebrelimab injection. |
| DRUG | Bevacizumab Injection | Bevacizumab injection. |
Timeline
- Start date
- 2025-07-22
- Primary completion
- 2031-10-01
- Completion
- 2031-10-01
- First posted
- 2025-07-17
- Last updated
- 2026-03-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07071714. Inclusion in this directory is not an endorsement.